2-氨基-3-氯-5-甲基吡嗪 | 89182-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-3-氯-5-甲基吡嗪
• 中文别名: 3-氯-5-甲基吡嗪-2-胺；3-氯-5-甲基-2-氨基吡嗪
• 英文名称: 3-chloro-5-methylpyrazin-2-amine
• CAS: 89182-14-9
• 化学式: C₅H₆ClN₃
• mdl: MFCD09834805
• 分子量: 143.576
• InChiKey: JPMJUTNVPDDMKZ-UHFFFAOYSA-N

物化性质

• 熔点：
  58-82℃
• 沸点：
  252.3±35.0℃ (760 Torr)
• 密度：
  1.349±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  106.4±25.9℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-3-chloro-5-methylpyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-3-chloro-5-methylpyrazine
CAS number: 89182-14-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6ClN3
Molecular weight: 143.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-3-氯-5-甲基吡嗪 在 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 异丙醇 为溶剂， 生成 3,6-dimethyl-8-(4-Boc-piperazinyl)amidazo<1,2-a>pyrazine
  参考文献：
  名称：

  取代的8-（1-哌嗪基）咪唑并[1,2-a]吡嗪的合成及降血糖活性。

  摘要：

  使用两种方法制备一系列烷基和卤素取代的8-（1-哌嗪基）咪唑并[1,2-a]吡嗪，α-卤代羰基衍生物与氨基吡嗪的缩合或[[（ β-羟烷基）氨基]吡嗪。评价这些咪唑并[1,2-a]吡嗪与α1，α2，β1和β2肾上腺素能受体的结合亲和力以及降低胰岛素抵抗性高血糖ob / ob小鼠血糖的能力。对8-（1-哌嗪基）咪唑并[1,2-a]吡嗪（4）的修饰减少了α2的结合，降低了降血糖的效力，并显示了与α1，β1和β2肾上腺素受体的结合变化。除了4种2-甲基，3-甲基和5-甲基8-（1-哌嗪基）咪唑并[1,2-a]吡嗪（16k，25m和16f，与2-氨基-7,8-二氢-4-（1-哌嗪基）-6H-硫代吡喃并[3,2-d]嘧啶（MTP- 1403，2）。通过使用4-甲基哌嗪部分修饰受体结合，该部分减少了α1和β1的结合，同时保留了一些降血糖活性。讨论了杂环烷基和卤素取代基对生物活性的构效关系。

  DOI：

  10.1021/jm00099a012
• 作为试剂：
  描述：

  2,6-二氟苄醇 、 potassium tert-butylate 、 2-amino-3-chloro-5-methylpyrazine hydrochloride 、 碳酸氢钠 在 2,6-二氟苄醇 、 2-氨基-3-氯-5-甲基吡嗪 、 二氯甲烷 、 氯化钠 、 magnesium sulfate 、 silica gel 、 cyclohexane, ethyl acetate 、 乙酸乙酯 作用下， 以 乙二醇二甲醚 为溶剂， 反应 17.0h， 以1.77 g of the title compound were obtained (39% of theory; 85% purity)的产率得到3-[(2,6-difluorobenzyl)oxy]-5-methylpyrazin-2-amine
  参考文献：
  名称：

  SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF

  摘要：

  本申请涉及新型取代咪唑[1,2-a]吡嗪羧酰胺、其制备方法、其单独或与其他药物联合治疗和/或预防疾病的用途，以及其用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病的药物。

  公开号：

  US20160176880A1

文献信息

• N-SUBSTITUTED 8-[(2,6-DIFLUOROBENZYL)OXY]-2,6-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-3-CARBOXAMIDE DERIVATIVES AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180022751A1

  公开（公告）日：2018-01-25

  The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新颖的取代咪唑[1,2-a]吡嗪羧酰胺，以及它们的制备方法，单独或与其他物质结合后用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170313700A1

  公开（公告）日：2017-11-02

  The present application relates to novel substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代的吡唑并[1,5-a]吡啶和咪唑并[1,2-a]吡嗪，以及其制备方法，用途，单独或组合用于治疗和/或预防疾病，以及用于生产药物治疗和/或预防疾病，特别是用于治疗和/或预防心血管疾病。
• Investigating the effects of the core nitrogen atom configuration on the thermodynamic solubility of 6,5-bicyclic heterocycles
  作者：Brett Cosgrove、Kenneth Down、Sophie Bertrand、Nicholas C.O. Tomkinson、Michael D. Barker

  DOI：10.1016/j.bmcl.2020.127752

  日期：2021.2

  as solubility, are important when prioritising compounds for progression on a drug discovery project. There is limited literature around the systematic effects of core changes on thermodynamic solubility. This work details the synthesis of nitrogen containing 6,5-bicyclic heterocyclic cores which are common scaffolds in medicinal chemistry and the analysis of their physicochemical properties, particularly

  在药物发现项目中优先考虑化合物的进展时，理化特性（例如溶解度）很重要。关于核心变化对热力学溶解度的系统影响的文献有限。这项工作详细介绍了含氮 6,5-双环杂环核的合成，这些核是药物化学中的常见支架，并分析了它们的理化特性，特别是热力学溶解度。在可能的情况下获得结晶固体，以便对热力学溶解度进行可靠的比较。还测量了其他参数，如 pKa、熔点和亲脂性，以确定影响观察到的溶解度的关键因素。
• [EN] TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY<br/>[FR] COMPOSÉS TRICYCLIQUES POUR DÉGRADER DES NÉO-SUBSTRATS POUR UNE THÉRAPIE MÉDICALE
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022081927A1

  公开（公告）日：2022-04-21

  The invention provides tricyclic compounds that degrade neosubstrates for use in the treatment of disorders described herein, including, for example, abnormal cellular proliferation, neurodegenerative diseases, and autoimmune diseases.

  本发明提供了三环化合物，用于治疗本文所述的疾病，包括但不限于异常细胞增殖、神经退行性疾病和自身免疫性疾病，这些化合物可以降解新的底物。
• Process for preparing alkoxypyrazine derivatives
  申请人：——

  公开号：US20010012894A1

  公开（公告）日：2001-08-09

  A process for preparing alkoxypyrazine derivatives of the general formula: 1 These alkoxypyrazine derivatives are obtained by reacting a glyoxal derivative of the general formula: 2 and an amimoimidate of the general formula: 3 The alkoxypyrazine derivatives are important intermediates for preparing pharmaceutically active compounds.

  一种制备通式为1的烷氧基吡嗪衍生物的方法：这些烷氧基吡嗪衍生物是通过将通式为2的丙二醛衍生物和通式为3的氨基咪唑酸盐反应得到的。这些烷氧基吡嗪衍生物是制备药物活性化合物的重要中间体。